Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

2009661 citationsJournal Articlebronze Open Access

Authors

Nancy U. Lin · Dana-Farber Cancer Institute

Véronique Dièras · Institut Curie

Devchand Paul · Rocky Mountain Cancer Centers

Dominique Lossignol · Institut Jules Bordet

Christos Christodoulou · Metropolitan Hospital

Hans‐Joachim Stemmler

Henri Roché · Institut Claudius Regaud

Abstract

This study confirms the modest CNS antitumor activity of lapatinib. Additional responses were observed with the combination of lapatinib and capecitabine. Further studies of lapatinib-based regimens for CNS metastases from HER2+ breast cancer are warranted.

Topics & Keywords

Brain Metastases and Treatment HER2/EGFR in Cancer Research Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 15, Issue 4, pp. 1452-1459

DOI: 10.1158/1078-0432.ccr-08-1080

Field-Weighted Citation Impact: 44.54